# Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog)

- Link: https://www.thailand-business-news.com/pr-news/hanmi-signs-licensing-deal-with-lilly-for-sonefpeglutide-lapsglp-2-analog
- Published: 2026-06-01T10:09:00+07:00
- Author: PR Newswire

|   |

**Lilly licenses Hanmi’s sonefpeglutide (LAPSGLP-2 analog) for multiple indications**

SEOUL, South Korea, June 1, 2026 /PRNewswire/ — Hanmi Pharm. Co., Ltd. ("Hanmi")
today announced that they have entered into a license agreement for the development,
manufacturing and commercialization of Hanmi’s biologic drug candidate sonefpeglutide(
^(LAPS)GLP-2 analog) with Eli Lilly and Company ("Lilly").

Sonefpeglutide is a novel drug candidate incorporating Hanmi’s proprietary long-
acting platform technology, LAPSCOVERY™. Hanmi has previously received FDA marketing
approval for a biologic incorporating its LAPSCOVERY platform and is currently conducting
additional global clinical trials for five other programs utilizing the same platform.

Hanmi has focused on the biological functions of glucagon-like peptide 2 (GLP-2)–
including the promotion of intestinal growth, reduction of inflammation, and protection
and regeneration of the intestinal mucosa – and has demonstrated these effects through
a range of non-clinical studies. The company has also presented the therapeutic 
potential of ^(LAPS)GLP-2 across multiple indications at major scientific conferences.
Hanmi is currently conducting a global Phase 2 clinical trial in short bowel syndrome(
SBS).

Hanmi will continue to conduct the ongoing global Phase 2 trial in SBS through completion
while Lilly will explore additional clinical trials for sonefpeglutide based on 
its nonclinical and clinical data.

Through this agreement, Lilly will obtain exclusive rights to develop, manufacture
and commercialize sonefpeglutide worldwide, excluding Korea.

Juhyun Lim, Vice Chairman of Hanmi, stated, "It is highly meaningful that Lilly—
one of the most closely watched innovators globally—has highly recognized the development
potential for sonefpeglutide." She added, "Hanmi will continue to advance innovative
drug development, guided by our mission of ‘Respect for People and Value Creation.’"

Under the agreement, Hanmi will receive an upfront payment of USD 75 million and
may receive up to an additional USD 1.185 billion in clinical development, regulatory
approval and commercialization milestone payments. In addition, Hanmi will be eligible
to receive royalties following product launch.

**About** **Hanmi Pharm. Co., Ltd.**

 Hanmi is an R&D-focused pharmaceutical company committed to developing globally
innovative therapies in areas of high unmet medical needs such as obesity/metabolism,
oncology, and rare diseases. Hanmi leverages proprietary platform technologies, 
including long-acting biologics and bispecific antibodies, to address unmet medical
needs. The company emphasizes open innovation and has established numerous global
partnerships to advance its research and development efforts. For more information,
please visit [www.hanmipharm.com](https://www.hanmipharm.com/). 

Contact info:
Hanmi Pharm. Co., Ltd. ([www.hanmipharm.com](http://www.hanmipharm.com/),
[www.linkedin.com/company/hanmipharm](http://www.linkedin.com/company/hanmipharm))
[innovation@hanmi.co.kr](https://www.thailand-business-news.com/pr-news/innovation@hanmi.co.kr),
+82-02-410-0467

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog) ](http://www.prnasia.com/story/archive/4972153_CN72153_0?rand=184833)